首页 > 最新文献

Canadian Journal of Neurological Sciences最新文献

英文 中文
The impact of inter-hospital transfer before endovascular thrombectomy on long-term outcomes after acute ischemic stroke. 血管内取栓前医院间转院对急性缺血性脑卒中远期预后的影响
IF 2.2 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-01-30 DOI: 10.1017/cjn.2026.10551
Robert Murphy, Zhixing Hong, Jiming Fang, Peter C Austin, Moira K Kapral, Amy Y X Yu
{"title":"The impact of inter-hospital transfer before endovascular thrombectomy on long-term outcomes after acute ischemic stroke.","authors":"Robert Murphy, Zhixing Hong, Jiming Fang, Peter C Austin, Moira K Kapral, Amy Y X Yu","doi":"10.1017/cjn.2026.10551","DOIUrl":"https://doi.org/10.1017/cjn.2026.10551","url":null,"abstract":"","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-21"},"PeriodicalIF":2.2,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146088207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychometric Validation of the French-Canadian Version of the Tampa Scale of Kinesiophobia for Parkinson's Disease. 法加版帕金森病运动恐惧症坦帕量表的心理计量学验证。
IF 2.2 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-01-28 DOI: 10.1017/cjn.2025.10509
Nicolas Mougeot, Jerry D'Meza, Giulia Corno, Joseph Saade, Guillaume Léonard, Alexandra Potvin-Desrochers

Background: Kinesiophobia is defined as an excessive and irrational fear of movement and physical activity. Individuals living with Parkinson's disease (PD) can be at risk of developing this phobia, due to the debilitating nature of the disease's motor symptoms such as impaired balance, bradykinesia, rigidity and tremor. This is particularly problematic, as exercise is crucial for people with PD, especially considering its potential to slow down disease progression. The Tampa Scale of Kinesiophobia for Parkinson's disease (TSK-PD) is a valid and reliable instrument for measuring kinesiophobia in PD. However, no French translation of this scale existed prior to this study.

Methods: The English TSK-PD was translated, cross-culturally adapted into Canadian French, and administered to 102 ambulatory French-speaking Canadians living with PD, aged 46-83. Statistical analyses were then conducted to examine the psychometric properties of the translated scale.

Results: Results confirmed the construct validity of the translated version and revealed high internal consistency (Cronbach's alpha = 0.90), good test-retest reliability (ICC = 0.84), with no evidence of floor or ceiling effects. Exploratory and confirmatory factor analyses supported a two-factor structure consisting of "Activity Avoidance" and "Harm."

Conclusion: The French-Canadian TSK-PD can be recommended for use in research and in clinical settings to better identify fear of movement in French-speaking PD patients and promote physical activity.

背景:运动恐惧症被定义为对运动和身体活动的过度和非理性恐惧。帕金森氏症(PD)患者可能有患上这种恐惧症的风险,因为这种疾病的运动症状会使人虚弱,比如平衡受损、运动迟缓、僵硬和震颤。这是特别有问题的,因为运动对帕金森病患者至关重要,特别是考虑到它有可能减缓疾病进展。坦帕帕金森病运动恐惧症量表(TSK-PD)是一种有效、可靠的帕金森病运动恐惧症量表。然而,在本研究之前,没有该量表的法语译本。方法:将英文TSK-PD翻译成跨文化的加拿大法语,并对102名46-83岁的加拿大法语患者进行管理。然后进行统计分析,以检验翻译后的量表的心理测量特性。结果:结果证实了译文的结构效度,内部一致性高(Cronbach’s alpha = 0.90),重测信度好(ICC = 0.84),没有证据表明存在地板效应或天花板效应。探索性和验证性因素分析支持由“活动避免”和“伤害”组成的双因素结构。结论:法裔加拿大人TSK-PD可以推荐用于研究和临床环境,以更好地识别法语PD患者的运动恐惧并促进身体活动。
{"title":"Psychometric Validation of the French-Canadian Version of the Tampa Scale of Kinesiophobia for Parkinson's Disease.","authors":"Nicolas Mougeot, Jerry D'Meza, Giulia Corno, Joseph Saade, Guillaume Léonard, Alexandra Potvin-Desrochers","doi":"10.1017/cjn.2025.10509","DOIUrl":"https://doi.org/10.1017/cjn.2025.10509","url":null,"abstract":"<p><strong>Background: </strong>Kinesiophobia is defined as an excessive and irrational fear of movement and physical activity. Individuals living with Parkinson's disease (PD) can be at risk of developing this phobia, due to the debilitating nature of the disease's motor symptoms such as impaired balance, bradykinesia, rigidity and tremor. This is particularly problematic, as exercise is crucial for people with PD, especially considering its potential to slow down disease progression. The Tampa Scale of Kinesiophobia for Parkinson's disease (TSK-PD) is a valid and reliable instrument for measuring kinesiophobia in PD. However, no French translation of this scale existed prior to this study.</p><p><strong>Methods: </strong>The English TSK-PD was translated, cross-culturally adapted into Canadian French, and administered to 102 ambulatory French-speaking Canadians living with PD, aged 46-83. Statistical analyses were then conducted to examine the psychometric properties of the translated scale.</p><p><strong>Results: </strong>Results confirmed the construct validity of the translated version and revealed high internal consistency (Cronbach's alpha = 0.90), good test-retest reliability (ICC = 0.84), with no evidence of floor or ceiling effects. Exploratory and confirmatory factor analyses supported a two-factor structure consisting of \"Activity Avoidance\" and \"Harm.\"</p><p><strong>Conclusion: </strong>The French-Canadian TSK-PD can be recommended for use in research and in clinical settings to better identify fear of movement in French-speaking PD patients and promote physical activity.</p>","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146068307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peripheral Indicators of Alzheimer's Disease Pathology in Women With Polycystic Ovary Syndrome: A Case-Control Study. 多囊卵巢综合征妇女阿尔茨海默病病理的外周指标:一项病例对照研究
IF 2.2 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-01-23 DOI: 10.1017/cjn.2025.10495
Bao Xing, Pang Xiaoqing, Zhang Yan

Background: Emerging evidence suggests that metabolic and hormonal disturbances in polycystic ovary syndrome (PCOS) may increase vulnerability to neurodegenerative disorders. However, the link between PCOS and Alzheimer's disease (AD)-related pathology remains unclear.

Methods: In this cross-sectional study, plasma levels of β-amyloid (Aβ40, Aβ42), phosphorylated tau (p-tau181), neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) were quantified in women with PCOS and age-matched controls. Homeostasis model assessment of insulin resistance (HOMA-IR), inflammatory cytokines (IL-6, TNF-α) and hormonal parameters were assessed. Mediation and moderation analyses were conducted to explore metabolic and hormonal pathways underlying biomarker alterations.

Results: Among 400 women (200 PCOS, 200 controls), age and BMI were comparable (P > 0.05). Compared with controls, PCOS participants had increased Aβ40, p-tau181, NfL and GFAP, a slightly higher Aβ42, and a lower Aβ42/40 ratio (all P < 0.05). p-tau181 correlated positively with HOMA-IR (r = 0.41) and IL-6 (r = 0.36), while Aβ42/40 ratio correlated negatively with HOMA-IR (r = -0.27). In multivariable analysis, p-tau181 (aOR = 1.34, 95% CI 1.05-1.71), IL-6 (aOR = 1.19) and TNF-α (aOR = 1.14) were independent predictors of insulin resistance. Mediation analysis indicated that HOMA-IR, IL-6 and TNF-α jointly mediated ∼ 71% of the PCOS-p-tau181 association, suggesting a metabolic-inflammatory pathway linking PCOS to AD-related tau pathology.

Conclusions: PCOS is linked to peripheral markers of early Alzheimer's pathology, largely mediated by insulin resistance and inflammation. PCOS may provide a clinical context to explore metabolic-inflammatory contributors to early neurodegenerative changes.

背景:越来越多的证据表明,多囊卵巢综合征(PCOS)的代谢和激素紊乱可能增加神经退行性疾病的易感性。然而,多囊卵巢综合征与阿尔茨海默病(AD)相关病理之间的联系尚不清楚。方法:在这项横断研究中,定量测定PCOS女性和年龄匹配对照组血浆中β-淀粉样蛋白(a - β40、a - β42)、磷酸化tau蛋白(p-tau181)、神经丝轻链(NfL)和胶质纤维酸性蛋白(GFAP)的水平。评估胰岛素抵抗(HOMA-IR)、炎症因子(IL-6、TNF-α)和激素参数的稳态模型评估。进行了中介和调节分析,以探索生物标志物改变背后的代谢和激素途径。结果:400例女性(PCOS 200例,对照组200例),年龄和BMI具有可比性(P < 0.05)。与对照组相比,PCOS患者a β40、P -tau181、NfL和GFAP升高,a β42略升高,a β42/40比值降低(均P < 0.05)。p-tau181与HOMA-IR呈正相关(r = 0.41),与IL-6呈正相关(r = 0.36),而a - β42/40与HOMA-IR呈负相关(r = -0.27)。在多变量分析中,p-tau181 (aOR = 1.34, 95% CI 1.05-1.71)、IL-6 (aOR = 1.19)和TNF-α (aOR = 1.14)是胰岛素抵抗的独立预测因子。中介分析表明,HOMA-IR、IL-6和TNF-α共同介导了约71%的PCOS-p-tau181关联,表明代谢炎症途径将PCOS与ad相关的tau病理联系起来。结论:多囊卵巢综合征与早期阿尔茨海默病病理的外周标志物有关,主要由胰岛素抵抗和炎症介导。多囊卵巢综合征可能为探索早期神经退行性改变的代谢炎症因素提供临床背景。
{"title":"Peripheral Indicators of Alzheimer's Disease Pathology in Women With Polycystic Ovary Syndrome: A Case-Control Study.","authors":"Bao Xing, Pang Xiaoqing, Zhang Yan","doi":"10.1017/cjn.2025.10495","DOIUrl":"https://doi.org/10.1017/cjn.2025.10495","url":null,"abstract":"<p><strong>Background: </strong>Emerging evidence suggests that metabolic and hormonal disturbances in polycystic ovary syndrome (PCOS) may increase vulnerability to neurodegenerative disorders. However, the link between PCOS and Alzheimer's disease (AD)-related pathology remains unclear.</p><p><strong>Methods: </strong>In this cross-sectional study, plasma levels of <i>β</i>-amyloid (Aβ<sub>40</sub>, Aβ<sub>42</sub>), phosphorylated tau (p-tau181), neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) were quantified in women with PCOS and age-matched controls. Homeostasis model assessment of insulin resistance (HOMA-IR), inflammatory cytokines (IL-6, TNF-<i>α)</i> and hormonal parameters were assessed. Mediation and moderation analyses were conducted to explore metabolic and hormonal pathways underlying biomarker alterations.</p><p><strong>Results: </strong>Among 400 women (200 PCOS, 200 controls), age and BMI were comparable (<i>P</i> > 0.05). Compared with controls, PCOS participants had increased Aβ<sub>40</sub>, p-tau181, NfL and GFAP, a slightly higher Aβ<sub>42</sub>, and a lower A<i>β</i><sub>42</sub>/<sub>40</sub> ratio (<i>all P</i> < 0.05). p-tau181 correlated positively with HOMA-IR (<i>r</i> = 0.41) and IL-6 (<i>r</i> = 0.36), while Aβ<sub>42</sub>/<sub>40</sub> ratio correlated negatively with HOMA-IR (<i>r</i> = -0.27). In multivariable analysis, p-tau181 (aOR = 1.34, 95% CI 1.05-1.71), IL-6 (aOR = 1.19) and TNF-<i>α</i> (aOR = 1.14) were independent predictors of insulin resistance. Mediation analysis indicated that HOMA-IR, IL-6 and TNF-<i>α</i> jointly mediated ∼ 71% of the PCOS-p-tau181 association, suggesting a metabolic-inflammatory pathway linking PCOS to AD-related tau pathology.</p><p><strong>Conclusions: </strong>PCOS is linked to peripheral markers of early Alzheimer's pathology, largely mediated by insulin resistance and inflammation. PCOS may provide a clinical context to explore metabolic-inflammatory contributors to early neurodegenerative changes.</p>","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146031868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Geographic Modelling of Endovascular Treatment Access Across Canada Demonstrates Need to Lower Door-in-Door-Out Times. 加拿大血管内治疗的地理模型表明需要降低门到门到门的时间。
IF 2.2 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-01-22 DOI: 10.1017/cjn.2025.10497
Noreen Kamal, Borna Baradaran-Noveiri, Jack Barrie, Jessalyn K Holodinsky, Denise St Louis, Andrew M Demchuk

Background: Timely access to endovascular treatment (EVT) for ischaemic stroke patients is critical for optimal outcomes, but Canada's size and population distribution create barriers to access. EVT is mostly available in tertiary centres located in large urban cities, and patients that arrive at intravenous thrombolysis (IVT)-only stroke centres need to be transferred for EVT.

Methods: Geographic modelling of access to an IVT-only centre and an EVT-capable centre was conducted for Canada. Canada was divided into small grid sections. Drive times from the centre of each grid section to the closest stroke centres and the population of each grid section were obtained. The onset to paramedic arrival time and on-scene time were assumed to be 30 and 30 minutes, respectively. In the suboptimal and optimal scenarios, the door-in-door-out (DIDO) times were 150 minutes and 45 minutes, respectively. The poor access regions and population were calculated for onset to thrombolysis at 4.5 hours and to EVT-capable centre arrival for EVT within 6 and 3 hours.

Results: The results show 99.37% of the population having access to thrombolysis within 4.5 hours. However, with a suboptimal DIDO time, 13.6% (5.2 million people) and 42.7% (16.2 million people) do not have access to EVT within 6 and 3 hours, respectively. With an efficient DIDO time, an additional 5.6% (2.1 million people) and 15.7% (6.0 million people) have access to EVT within 6 and 3 hours, respectively.

Conclusion: There is an imperative to reduce DIDO times to an ambitious median of 45 minutes to ensure optimal access to EVT across Canada.

背景:缺血性脑卒中患者及时获得血管内治疗(EVT)对于获得最佳结果至关重要,但加拿大的面积和人口分布造成了获得血管内治疗的障碍。EVT主要在大城市的三级中心提供,到达仅提供静脉溶栓治疗的卒中中心的患者需要转院接受EVT治疗。方法:在加拿大对仅使用evt的中心和能够使用evt的中心进行地理建模。加拿大被划分成网格状的小区域。获得了从每个网格段中心到最近的冲程中心的驱动次数和每个网格段的人口。假定从发病到护理人员到达的时间和到达现场的时间分别为30分钟和30分钟。在次优和最优场景下,从门到门到门的时间分别为150分钟和45分钟。计算了交通不便地区和人口在4.5小时内开始溶栓,并在6小时和3小时内到达能够进行EVT的中心。结果:99.37%的人群在4.5小时内获得溶栓。然而,在DIDO时间不理想的情况下,分别有13.6%(520万人)和42.7%(1620万人)在6小时和3小时内无法获得EVT。在有效的DIDO时间内,分别有5.6%(210万人)和15.7%(600万人)在6小时和3小时内获得EVT。结论:有必要将DIDO时间减少到45分钟的中位数,以确保在加拿大全境获得最佳的EVT。
{"title":"Geographic Modelling of Endovascular Treatment Access Across Canada Demonstrates Need to Lower Door-in-Door-Out Times.","authors":"Noreen Kamal, Borna Baradaran-Noveiri, Jack Barrie, Jessalyn K Holodinsky, Denise St Louis, Andrew M Demchuk","doi":"10.1017/cjn.2025.10497","DOIUrl":"https://doi.org/10.1017/cjn.2025.10497","url":null,"abstract":"<p><strong>Background: </strong>Timely access to endovascular treatment (EVT) for ischaemic stroke patients is critical for optimal outcomes, but Canada's size and population distribution create barriers to access. EVT is mostly available in tertiary centres located in large urban cities, and patients that arrive at intravenous thrombolysis (IVT)-only stroke centres need to be transferred for EVT.</p><p><strong>Methods: </strong>Geographic modelling of access to an IVT-only centre and an EVT-capable centre was conducted for Canada. Canada was divided into small grid sections. Drive times from the centre of each grid section to the closest stroke centres and the population of each grid section were obtained. The onset to paramedic arrival time and on-scene time were assumed to be 30 and 30 minutes, respectively. In the suboptimal and optimal scenarios, the door-in-door-out (DIDO) times were 150 minutes and 45 minutes, respectively. The poor access regions and population were calculated for onset to thrombolysis at 4.5 hours and to EVT-capable centre arrival for EVT within 6 and 3 hours.</p><p><strong>Results: </strong>The results show 99.37% of the population having access to thrombolysis within 4.5 hours. However, with a suboptimal DIDO time, 13.6% (5.2 million people) and 42.7% (16.2 million people) do not have access to EVT within 6 and 3 hours, respectively. With an efficient DIDO time, an additional 5.6% (2.1 million people) and 15.7% (6.0 million people) have access to EVT within 6 and 3 hours, respectively.</p><p><strong>Conclusion: </strong>There is an imperative to reduce DIDO times to an ambitious median of 45 minutes to ensure optimal access to EVT across Canada.</p>","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146019991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Longest Intracranial/Subarachnoid Cranial Nerve. 最长颅内/蛛网膜下腔脑神经。
IF 2.2 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-01-22 DOI: 10.1017/cjn.2025.10508
Onder Ertem
{"title":"Longest Intracranial/Subarachnoid Cranial Nerve.","authors":"Onder Ertem","doi":"10.1017/cjn.2025.10508","DOIUrl":"https://doi.org/10.1017/cjn.2025.10508","url":null,"abstract":"","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1"},"PeriodicalIF":2.2,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146020399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A mixed perfusion pattern on Single Photon Emission Computed Tomography in Hashimoto's encephalopathy. 桥本脑病单光子发射计算机断层扫描的混合灌注模式。
IF 2.2 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-01-21 DOI: 10.1017/cjn.2026.10534
Taiki Matsubayashi, Ryoko Muramatsu, Misako Furuki, Masato Obayashi
{"title":"A mixed perfusion pattern on Single Photon Emission Computed Tomography in Hashimoto's encephalopathy.","authors":"Taiki Matsubayashi, Ryoko Muramatsu, Misako Furuki, Masato Obayashi","doi":"10.1017/cjn.2026.10534","DOIUrl":"https://doi.org/10.1017/cjn.2026.10534","url":null,"abstract":"","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-7"},"PeriodicalIF":2.2,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146013428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Geographic Differences in Healthcare Utilization Outcomes in Ischemic Stroke: A Population-level Study from Manitoba. 缺血性卒中医疗保健利用结果的地理差异:马尼托巴省的一项人口水平研究
IF 2.2 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-01-20 DOI: 10.1017/cjn.2026.10533
Angela Buchel, A Zohaib Siddiqi, Esseddeeg Ghrooda, Anurag Trivedi, Ankur Wadhwa, Claudia Candale-Radu, Radhika Kadangot, Babawale Arabambi, Chetan Vekhande, Naveed Akhtar, Nima Kashani, Nishita Singh
{"title":"Geographic Differences in Healthcare Utilization Outcomes in Ischemic Stroke: A Population-level Study from Manitoba.","authors":"Angela Buchel, A Zohaib Siddiqi, Esseddeeg Ghrooda, Anurag Trivedi, Ankur Wadhwa, Claudia Candale-Radu, Radhika Kadangot, Babawale Arabambi, Chetan Vekhande, Naveed Akhtar, Nima Kashani, Nishita Singh","doi":"10.1017/cjn.2026.10533","DOIUrl":"https://doi.org/10.1017/cjn.2026.10533","url":null,"abstract":"","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-20"},"PeriodicalIF":2.2,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146004787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perceived Cognitive Fatigability in Multiple Sclerosis: Input from People with Lived Experience on Unmet Needs. 多发性硬化症的认知疲劳:来自未满足需求的生活经验的人的输入。
IF 2.2 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-01-20 DOI: 10.1017/cjn.2026.10531
Tamanna Islam, Jason A Berard, Lisa A S Walker

Purpose: Cognitive fatigability (CF), which refers to a decline in performance during sustained cognitive effort, can significantly impact people with multiple sclerosis (PwMS). This study examined the unmet needs related to perceived CF in PwMS.

Methods: One hundred PwMS completed a survey assessing factors known to contribute to CF. Participants indicated whether each factor, including CF itself, was disruptive and whether adequate support was available to address these concerns. A factor identified as disruptive and insufficiently addressed was considered an unmet need (Need Index [NI] ≥50%).

Results: Group-level analysis revealed no significant unmet needs, although fatigue (NI = 30.23), CF (NI = 22.96) and physical activity (NI = 19.55) were more frequently reported. Individual-level analyses revealed that unmet needs varied by community setting (rural vs urban) and socioeconomic status (SES) (lower vs higher SES), with rural participants and those with lower SES reporting higher rates of unmet needs. In addition, PwMS who indicated CF was an unmet need reported more difficulties across most contributory factors, including sleep quality, fatigue, cognitive impairment, depression and contextual factors. The presence of fatigue and CF combined contributed to greater unmet needs across various domains, especially fatigue, CF and cognitive impairment, compared to fatigue alone.

Conclusions: Participants from rural and low socioeconomic backgrounds were more likely to have unmet needs. Notably, 36% of participants (N = 33) reported unmet needs related to perceived CF. The findings highlight the importance of tailoring future interventions to address identified needs more adequately.

目的:认知疲劳(CF)是指在持续认知努力过程中表现的下降,对多发性硬化症(PwMS)患者有显著影响。本研究调查了PwMS患者与感知CF相关的未满足需求。方法:100名PwMS完成了一项调查,评估了已知的导致CF的因素。参与者指出每个因素,包括CF本身,是否具有破坏性,以及是否有足够的支持来解决这些问题。被确定为破坏性且未得到充分解决的因素被认为是未满足的需求(需求指数[NI]≥50%)。结果:组水平分析显示,尽管疲劳(NI = 30.23)、CF (NI = 22.96)和体力活动(NI = 19.55)的报告频率较高,但未满足需求的情况并不明显。个人层面的分析显示,未满足的需求因社区环境(农村与城市)和社会经济地位(SES)(低SES与高SES)而异,农村参与者和社会经济地位较低的参与者报告的未满足需求率较高。此外,指出CF是一个未满足需求的PwMS报告了更多的困难,包括睡眠质量、疲劳、认知障碍、抑郁和环境因素。与单独的疲劳相比,疲劳和CF的存在导致了各个领域更大的未满足需求,特别是疲劳、CF和认知障碍。结论:来自农村和低社会经济背景的参与者更有可能有未满足的需求。值得注意的是,36%的参与者(N = 33)报告了与感知到的CF相关的未满足需求。研究结果强调了定制未来干预措施以更充分地解决已确定需求的重要性。
{"title":"Perceived Cognitive Fatigability in Multiple Sclerosis: Input from People with Lived Experience on Unmet Needs.","authors":"Tamanna Islam, Jason A Berard, Lisa A S Walker","doi":"10.1017/cjn.2026.10531","DOIUrl":"10.1017/cjn.2026.10531","url":null,"abstract":"<p><strong>Purpose: </strong>Cognitive fatigability (CF), which refers to a decline in performance during sustained cognitive effort, can significantly impact people with multiple sclerosis (PwMS). This study examined the unmet needs related to perceived CF in PwMS.</p><p><strong>Methods: </strong>One hundred PwMS completed a survey assessing factors known to contribute to CF. Participants indicated whether each factor, including CF itself, was disruptive and whether adequate support was available to address these concerns. A factor identified as disruptive and insufficiently addressed was considered an unmet need (Need Index [NI] ≥50%).</p><p><strong>Results: </strong>Group-level analysis revealed no significant unmet needs, although fatigue (NI = 30.23), CF (NI = 22.96) and physical activity (NI = 19.55) were more frequently reported. Individual-level analyses revealed that unmet needs varied by community setting (rural vs urban) and socioeconomic status (SES) (lower vs higher SES), with rural participants and those with lower SES reporting higher rates of unmet needs. In addition, PwMS who indicated CF was an unmet need reported more difficulties across most contributory factors, including <i>sleep quality</i>, <i>fatigue</i>, <i>cognitive impairment</i>, <i>depression</i> and <i>contextual factors</i>. The presence of fatigue and CF combined contributed to greater unmet needs across various domains, especially <i>fatigue</i>, <i>CF</i> and <i>cognitive impairment</i>, compared to fatigue alone.</p><p><strong>Conclusions: </strong>Participants from rural and low socioeconomic backgrounds were more likely to have unmet needs. Notably, 36% of participants (<i>N</i> = 33) reported unmet needs related to perceived CF. The findings highlight the importance of tailoring future interventions to address identified needs more adequately.</p>","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146004816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reviewer Comment on Randall et al. "Calcitonin Gene-Related Peptide Inhibitor Use in 2018-2023: A Retrospective Cohort Study Across Six Canadian Provinces". 对Randall等人的评论。2018-2023年降钙素基因相关肽抑制剂的使用:一项横跨加拿大六个省的回顾性队列研究。
IF 2.2 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-01-20 DOI: 10.1017/cjn.2025.10507
Ioana Medrea
{"title":"Reviewer Comment on Randall et al. \"Calcitonin Gene-Related Peptide Inhibitor Use in 2018-2023: A Retrospective Cohort Study Across Six Canadian Provinces\".","authors":"Ioana Medrea","doi":"10.1017/cjn.2025.10507","DOIUrl":"https://doi.org/10.1017/cjn.2025.10507","url":null,"abstract":"","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1"},"PeriodicalIF":2.2,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146004835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CAPS Plus: A clinical biomarker scoring system to predict Aβ positivity and facilitate enrolment in anti-amyloid clinical trials. CAPS Plus:一种临床生物标志物评分系统,用于预测Aβ阳性并促进抗淀粉样蛋白临床试验的登记。
IF 2.2 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-01-20 DOI: 10.1017/cjn.2026.10530
Durjoy Lahiri, Jennifer G Cooper, Bruna Seixas-Lima, Carlos Roncero, Cheryl L Wellington, Howard Chertkow
{"title":"CAPS Plus: A clinical biomarker scoring system to predict Aβ positivity and facilitate enrolment in anti-amyloid clinical trials.","authors":"Durjoy Lahiri, Jennifer G Cooper, Bruna Seixas-Lima, Carlos Roncero, Cheryl L Wellington, Howard Chertkow","doi":"10.1017/cjn.2026.10530","DOIUrl":"https://doi.org/10.1017/cjn.2026.10530","url":null,"abstract":"","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-22"},"PeriodicalIF":2.2,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146004771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Canadian Journal of Neurological Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1